RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$12.99
+3.51% today
Updated 2026-04-29
Market cap
$201.54M
P/E ratio
—
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
—
52W range
$12 – $17
Volume
1.5M
Atrium Therapeutics, Inc. Common Stock (RNA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $32.68M | $62.41M | $125.10M | $3.98M | $96.91M | $333.90M | $427.58M | $638.80M | $628.55M | $1.56B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — |
| Current assets | — | — | — | $3.24M | $95.68M | $331.68M | $411.14M | $622.94M | $611.31M | $1.54B |
| Total liabilities | $29.27M | $41.87M | $38.00M | $45.11M | $162.26M | $27.68M | $46.15M | $60.73M | $127.79M | $138.94M |
| Current liabilities | $15.46M | $16.07M | $12.51M | $4.62M | $10.24M | $14.59M | $29.66M | $51.91M | $80.68M | $98.02M |
| Long-term debt | $3.24M | $8.17M | $10.51M | $7.58M | $1.77M | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | — | — | — | $-41.55M | $-22.18M | $-66.54M | $-184.55M | $-358.54M | $-570.76M | $-893.07M |
| Accounts receivable | — | — | — | — | $800000.00 | $1.20M | $900000.00 | $3.88M | $8.62M | $28.22M |
| Inventory | — | — | — | — | $1.00 | $-1.20M | $-900000.00 | $1.00 | $-7.33M | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |